Trial Profile
A trial to evaluate absolute lymphocyte counts (ALCs) in patients with multiple sclerosis (MS) treated with delayed-release dimethyl fumarate (DMF) using data from two US electronic health record (EHR) databases
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2016
Price :
$35
*
At a glance
- Drugs Dimethyl fumarate (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 03 May 2016 New trial record
- 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology